US Patent 11,008,289: What the Claims Actually Cover and How the Landscape Maps
US Patent 11,008,289 is a method-of-treatment patent that ties chronic obstructive pulmonary disease (COPD) therapy to a specific crystalline freebase solid form of a defined active pharmaceutical ingredient (API) and to a specific delivery method: nebulization of an aqueous pharmaceutical composition.
The legal scope is driven by three claim pillars:
- The crystalline freebase identity is locked to X-ray diffraction (XRPD) peak positions and optional add-on peaks.
- The method is limited to COPD treatment in a human and requires administration by nebulizer.
- Formulation parameters are partially claimed (isotonic, pH 4 to 6, citrate buffer to pH ~5, and concentration range).
What Is the Claimed Invention in Plain Claim Terms?
Claim 1: Core method scope
Claim 1 requires all elements below in combination:
A. Clinical indication
- Treating chronic obstructive pulmonary disease in a human patient.
B. Formulation step
- Preparing a pharmaceutical composition by dissolving a crystalline freebase of a specific chemical entity:
- “biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}-ethyl)piperidin-4-yl ester” (as written in the claim).
- Dissolving it in an aqueous pharmaceutical carrier.
C. Solid-state identity constraint (XRPD)
- The crystalline freebase is characterized by an XRPD powder pattern with diffraction peaks at specific 2θ values:
- 6.6 ± 0.1
- 13.1 ± 0.1
- 18.6 ± 0.1
- 19.7 ± 0.1
- 20.2 ± 0.1
D. Administration mode
- Administering the prepared aqueous composition to the patient using a nebulizer.
Claim 2: Expansion via additional XRPD peaks
Claim 2 retains Claim 1’s requirements and adds:
- The crystalline freebase further has five or more additional diffraction peaks at 2θ values selected from a defined pool:
- 8.8, 10.1, 11.4, 11.6, 14.8, 15.2, 16.1, 16.4, 16.9, 17.5, 18.2, 19.3, 19.9, 20.8, 21.1, 21.7, 22.3 (each ±0.1).
Claims 3–5: Additional identity/characterization anchors
All depend on Claim 1:
- Claim 3: Peak positions “in accordance with FIG. 1.”
- Claim 4: Melting point ~125°C.
- Claim 5: DSC thermogram in accordance with FIG. 4.
Claims 6–9: Formulation parameter constraints
All depend on Claims 1–5:
- Claim 6: Composition is isotonic.
- Claim 7: Composition has pH about 4–6.
- Claim 8: Composition is buffered with citrate buffer to pH about 5.
- Claim 9: Composition contains about 0.05 μg/mL to about 10 mg/mL of the stated API.
Where the Claim Scope Is Strongest
1) The XRPD fingerprint narrows product design space
The solid-state requirement in Claim 1 functions like a gatekeeper. Any competitor attempting to practice the method must meet the crystalline freebase identity as measured by XRPD with the specified peak set.
| The “hard” portion is the five mandatory peaks: |
XRPD peak (2θ) |
Tolerance |
| 6.6 |
±0.1 |
| 13.1 |
±0.1 |
| 18.6 |
±0.1 |
| 19.7 |
±0.1 |
| 20.2 |
±0.1 |
Claim 2 further restricts by requiring at least five additional peaks from a defined list, which reduces the range of acceptable variants.
2) Delivery by nebulizer is a separate limiting element
Claim 1’s method is not just COPD treatment. It is COPD treatment where administration is done “using a nebulizer.”
This matters because inhalation devices differ in:
- aerosol generation mechanism,
- droplet size distribution,
- formulation excipients needed for stability,
- and whether formulation must be water-based and compatible with nebulization.
3) The formulation is aqueous and includes specific optional constraints
Claim 1 already requires an aqueous carrier and dissolution of the crystalline freebase. Dependent claims add typical nebulizable formulation parameters:
- isotonicity (Claim 6),
- pH 4 to 6 (Claim 7),
- citrate buffer to pH ~5 (Claim 8),
- and concentration bounds (Claim 9).
Claim dependency structure means Claim 1 is the broadest. Claims 6–9 narrow further but still matter for infringement analysis because a practicing product may fit both independent and dependent claim sets.
Where the Claim Scope Leaves Room (and Why It Still Matters)
XRPD allows some room via measurement variation, but not free-form
The claim does not say “about” the peaks except through the ±0.1 tolerance. That makes the infringement test heavily dependent on:
- instrument calibration,
- sample preparation,
- measurement conditions,
- and whether the competitor’s solid form consistently exhibits the peak set.
Even so, Claim 1 does not rely on a single peak. It relies on a combination of five peaks. That combination is typically harder for substitutes to match unless the exact polymorph/crystalline form is used.
“Dissolving” in an aqueous carrier does not limit excipients broadly in Claim 1
Claim 1 says dissolve the crystalline freebase in an aqueous pharmaceutical carrier. It does not lock the composition to any particular buffer in Claim 1. Buffering, pH, isotonicity are in dependent claims (Claims 7–8 and 6). That means a product could still infringe Claim 1 even if it differs on pH and isotonicity, so long as it satisfies Claim 1’s elements.
Concentration range is only in Claim 9
The 0.05 μg/mL to 10 mg/mL concentration range is not in Claim 1. That range becomes relevant only for infringement of Claim 9 and any claims depending on it, not for Claim 1.
Claim-by-Claim Scope Map (Infringement Logic)
| Claim |
Adds beyond Claim 1 |
Key limiting features |
| 1 |
none |
COPD + human + aqueous dissolution + crystalline freebase with mandatory XRPD peaks at 6.6, 13.1, 18.6, 19.7, 20.2 + nebulizer administration |
| 2 |
additional XRPD constraint |
requires ≥5 additional peaks from specified 2θ set |
| 3 |
FIG-based XRPD equivalence |
peak positions “as shown in FIG. 1” |
| 4 |
thermal property |
melting point ~125°C |
| 5 |
thermal profile |
DSC thermogram as shown in FIG. 4 |
| 6 |
formulation property |
isotonic composition |
| 7 |
formulation pH |
pH about 4–6 |
| 8 |
buffering system and pH |
citrate buffer to pH about 5 |
| 9 |
concentration range |
~0.05 μg/mL to ~10 mg/mL |
What the Patent Landscape Likely Looks Like (Based on the Claim Architecture)
The claim architecture indicates a landscape structured around solid form patenting and device/formulation delivery routes:
- Solid-state patenting: crystalline freebase is defined via XRPD peaks, melting point, and DSC. This is classic for polymorph and form control.
- Route/device patenting: nebulizer delivery is tied into the method claims, limiting enforcement to nebulizable regimens.
- Indication patenting: “treating COPD” places the claim in therapeutic method territory rather than composition-of-matter territory.
Because you provided only the claim text and not the patent’s bibliographic data (filing date, assignee, related applications, prosecution history), a precise citation-level map of contemporaneous US applications, continuations, or family members cannot be reliably generated from the information provided.
What can be stated from the claim language itself is how competitors generally fragment their design strategies:
- Alternative solid forms (different polymorph/hydrate/amorphous) to avoid the XRPD peak set.
- Alternative salt forms or different chemical salt forms can evade a “freebase crystalline” definition if the product uses a different solid-state form. (Whether it truly avoids depends on whether the product still converts or exhibits the same XRPD peaks at dosing.)
- Non-nebulizer delivery (DPIs, pMDIs, soft mist inhalers) to avoid the nebulizer element.
- Different indication framing can avoid “COPD” if claims are strictly limited to COPD treatment (though regulatory labeling and physician use risks remain a separate enforcement question).
- pH/buffer deviation to evade dependent formulation claims (6–9) while still attempting to stay under Claim 1’s broader requirements.
Enforcement Priority: Which Claim Set a Litigant Will Hit First
First target: Claim 1
From a plaintiff’s standpoint, Claim 1 is the anchor because it contains:
- the therapeutic indication,
- the nebulizer administration mode,
- the aqueous formulation step,
- and the essential XRPD fingerprint.
Second target: Claim 2 for stronger solid-form confirmation
Claim 2 requires additional peaks and therefore can:
- make the XRPD match harder for defendants to challenge,
- reduce arguments that the “mandatory peaks” appear due to mixed phases or measurement noise.
Third target: dependent formulation claims when product is clearly fixed
If accused products are marketed as nebulizable solutions with defined pH and isotonic targets (common in regulatory packages), Claims 6–9 become practical leverage points.
Operational Risk for Competitors (Design-Around Checklist Based on the Claims)
A design-around that addresses only one element often fails. The claim structure requires matching multiple constraints simultaneously.
To avoid Claim 1, a competitor must break at least one of these
- Not treat COPD (hard in practice because COPD label matters, but it is a claim element).
- Not administer using a nebulizer.
- Not use the defined aqueous dissolution method of the crystalline freebase characterized by the mandatory XRPD peaks.
- Use a different solid form where the XRPD does not show the required 2θ peaks with ±0.1 tolerance.
To avoid Claims 6–9
Even if Claim 1 is avoided, a competitor that accidentally meets dependent claim constraints could still face additional exposure if Claim 1 is also met. Dependent claim targets are:
- isotonicity (Claim 6),
- pH 4 to 6 (Claim 7),
- citrate buffer to pH ~5 (Claim 8),
- concentration 0.05 μg/mL to 10 mg/mL (Claim 9).
Key Takeaways
- US 11,008,289 is a COPD treatment method claim that is inseparable from nebulizer administration and a specific crystalline freebase solid form defined by a five-peak XRPD fingerprint (6.6, 13.1, 18.6, 19.7, 20.2 at ±0.1).
- Claim 2 strengthens the XRPD match by requiring at least five additional peaks selected from a defined 2θ list.
- Claims 3–5 add thermal and figure-based identity anchors (FIG-based peak positions, melting point ~125°C, DSC profile), increasing evidentiary leverage in infringement testing.
- Claims 6–9 target common nebulizable formulation attributes (isotonicity, pH 4–6, citrate buffer pH ~5, and concentration range) but are dependent on Claim 1.
- A competitor’s design-around has to break one of the core constraints (COPD, nebulizer route, aqueous dissolution of the defined crystalline freebase, or the XRPD fingerprint). Addressing only pH or isotonicity will not avoid Claim 1.
FAQs
1) What is the single most important technical requirement in Claim 1?
The crystalline freebase identity defined by XRPD peaks at 2θ 6.6 ± 0.1, 13.1 ± 0.1, 18.6 ± 0.1, 19.7 ± 0.1, and 20.2 ± 0.1.
2) Does Claim 1 require citrate buffer?
No. Citrate buffer to pH about 5 is in Claim 8, which depends on Claim 1.
3) Is isotonicity required to infringe?
Not for Claim 1. Isotonicity is required only for Claim 6.
4) Can a non-nebulizer inhaler avoid infringement?
Claim 1 requires administration using a nebulizer. A different administration device is a direct route-based distinction against Claim 1.
5) Is the concentration range (0.05 μg/mL to 10 mg/mL) part of Claim 1?
No. That range is only in Claim 9.
References (APA)
No sources were cited because the prompt provides only the claim text for US 11,008,289 and does not include bibliographic or external-document details needed for a verifiable patent landscape with citations.
